EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent

Andrea Erriquez, David M Leistner, Valeria Paradies, Rita Pavasini, Matteo Serenelli, Gianni Casella, Simone Biscaglia, Christoph Naber, Gianluca Campo iD, Pieter C Smits

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31481 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Andrea Erriquez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Cona, Ferrara, Italy. Hauptthemen laut MEDLINE: Hemorrhage, Drug-Eluting Stents, Percutaneous Coronary Intervention, Sirolimus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The present analysis did not receive any economic support. However, Sahajanand Medical Technologies Ltd. (SMT) provided unrestricted funding for the conduction….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is limited evidence on the safety and efficacy of biodegradable‐polymer sirolimus‐eluting ultra‐thin stent (BP‐SES) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).

Aims

This study aims to evaluate the clinical outcomes of HBR patients treated with BP‐SES and ≤ 30‐day dual antiplatelet therapy (DAPT) regimen.

Methods

A systematic review was conducted to identify relevant studies involving HBR patients who underwent PCI with BP‐SES (Supraflex Cruz). Individual patient‐level data were extracted from the included studies. The primary endpoint was the composite of cardiovascular death, myocardial infarction, or clinically driven target lesion revascularization at 1‐year. The safety endpoint was the 1‐year occurrence of Bleeding Academic Research Consortium (BARC) type 3−5.

Results

The study population included 1691 patients. Of these, 928 patients (55%) received a ≤ 30‐day DAPT, while 763 patients (45%) received a longer DAPT regimen. In the ≤ 30‐day DAPT group, primary outcome events occurred in 89 patients (9.5%, 95% CI: 7.7%−11.6%). The upper limit of the one‐sided 95% CI of 11.6% was below the pre‐specified non‐inferiority margin of 14%. There was no significant difference in the primary endpoint between the ≤ 30‐day DAPT group and the >30‐day DAPT group (propensity score adjusted HR: 0.95, 95% CI: 0.67−3). Notably, the incidence of BARC 3−5 bleeding events was significantly lower in the ≤ 30‐day DAPT group.

Conclusions

In HBR patients treated with BP‐SES, a ≤ 30‐day DAPT regimen is associated with a low rate of ischemic events and a significant reduction in major bleeding events. Trial Registration: PROSPERO CRD42024524208.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhageDrug-Eluting StentsPercutaneous Coronary InterventionSirolimusPlatelet Aggregation InhibitorsAbsorbable ImplantsCoronary Artery DiseasePolymersCardiovascular AgentsDual Anti-Platelet TherapyHumansTime FactorsTreatment OutcomeRisk FactorsProsthesis DesignMaleRisk AssessmentFemaleAgedMiddle AgedDrug Administration Schedule

Stichwörter der Autor:innen

dual antiplatelet therapyhigh beeding riskmeta‐analysispercutaneous coronary interventionsirolimus‐eluting biodegradable polymer stent

Substanzen

SirolimusPlatelet Aggregation InhibitorsPolymersCardiovascular Agents

Autor:innen und Institutionen

  • Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Cona, Ferrara, Italy.
  • Department of Cardiology, Angiology and Intensive Care Medicine, Goethe University Hospital, Frankfurt, Germany.
  • Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.
  • Cardiology Unit, Ospedale Maggiore, Bologna, Italy.
  • Facharztpraxis Baldeney, Essen, Germany.

ORCID-Profile: Gianluca Campo

Förderung

  • The present analysis did not receive any economic support. However, Sahajanand Medical Technologies Ltd. (SMT) provided unrestricted funding for the conduction…

Zitieren

APA

Erriquez, A., Leistner, D. M., Paradies, V., Pavasini, R., Serenelli, M., Casella, G., Biscaglia, S., Naber, C., Campo, G., & Smits, P. C. (2025). 30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31481

Vancouver

Erriquez A, Leistner DM, Paradies V, Pavasini R, Serenelli M, Casella G, et al. 30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31481

BibTeX
@article{Erriquez2025,
  author = {Erriquez, Andrea and Leistner, David M and Paradies, Valeria and Pavasini, Rita and Serenelli, Matteo and Casella, Gianni and Biscaglia, Simone and Naber, Christoph and Campo, Gianluca and Smits, Pieter C},
  title = {30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31481}
}
Kostenlos starten →